Luis J V Galietta

Title: Innovations by Luis J V Galietta in Cystic Fibrosis Treatment

Introduction

Luis J V Galietta is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of cystic fibrosis research. He holds a total of 3 patents that focus on innovative compounds aimed at improving the treatment of this genetic disorder. His work has the potential to greatly enhance the quality of life for individuals affected by cystic fibrosis.

Latest Patents

One of his latest patents is titled "Compounds having activity in correcting mutant-CFTR processing and uses thereof." This invention provides compositions, pharmaceutical preparations, and methods for correcting cellular processing of a mutant-cystic fibrosis transmembrane conductance regulator protein, specifically targeting the ΔF508 CFTR mutation. The compositions may include various aminobenzothiazole-containing compounds and their analogs, which are useful for treating cystic fibrosis.

Another notable patent is "Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof." This invention focuses on increasing the activity of the mutant cystic fibrosis transmembrane conductance regulator protein, such as ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR. The compositions may comprise phenylglycine-containing compounds or sulfonamide-containing compounds, which are also beneficial for cystic fibrosis treatment.

Career Highlights

Luis J V Galietta is affiliated with the University of California, where he conducts his research and development work. His innovative approaches to addressing the challenges posed by cystic fibrosis have positioned him as a key figure in this area of medical research.

Collaborations

Throughout his career, Galietta has collaborated with notable researchers, including Alan S Verkman and R Kiplin Guy. These collaborations have further enriched his work and contributed to advancements in cystic fibrosis therapies.

Conclusion

Luis J V Galietta's contributions to cystic fibrosis research through his patents and collaborations highlight his commitment to improving patient outcomes. His innovative compounds and methods represent a significant step forward in the treatment of this challenging condition.